New trial data from Mass General Brigham suggest vitamin D3 taken after a COVID-19 diagnosis might slightly lower the chance of persistent symptoms weeks later, though it did not change how sick people got at the outset. The randomized study compared high-dose vitamin D3 to a placebo in recently infected adults and looked at household spread, acute outcomes, and lingering issues commonly grouped under long COVID.
The researchers set up a pragmatic, randomized clinical trial during a chaotic time, enrolling nearly eighteen hundred adults who had tested positive for COVID-19 and a few hundred household members. Participants were assigned to take either vitamin D3 supplements or an inactive pill for four weeks, and the team tracked symptom patterns, healthcare visits, and ongoing complaints in the weeks following infection. Conducting the study remotely meant the team had to rely on self-reporting and follow-up questionnaires rather than in-person assessments. That approach kept people safe and allowed rapid enrollment, but it also introduced limits in control and timing.
When the investigators crunched the numbers, they found no clear benefit for vitamin D in the short-term course of illness. Symptom intensity, emergency visits, and hospitalizations were similar whether people took the supplement or the placebo. Household transmission rates also showed no meaningful difference between the two groups, suggesting the supplement did not reduce the immediate spread within homes.
The most intriguing result showed up months later when researchers looked at ongoing symptoms. Among people who followed the supplement schedule carefully, about 21 percent of those on vitamin D reported at least one symptom eight weeks after infection, compared with roughly 25 percent in the placebo group. “A key takeaway is that vitamin D supplementation looks promising for reducing the risk of developing long COVID but does not appear to affect the severity of the acute infection,” Manson said.
The lead author highlighted the scope of the effort and the public curiosity around vitamin D and COVID. “There’s been tremendous interest in whether vitamin D supplements can be of benefit in COVID, and this is one of the largest and most rigorous randomized trials on the subject,” Manson said in the press release. She followed that up with a cautious note about the main findings. “While we didn’t find that high-dose vitamin D reduced COVID severity or hospitalizations, we observed a promising signal for long COVID that merits additional research,” she added.
Why might vitamin D affect lingering symptoms but not the acute phase? One plausible reason lies in how vitamin D interacts with the immune system. The nutrient helps modulate inflammatory responses and supports immune regulation, which could influence recovery trajectories long after the virus has cleared. If inflammation and immune dysregulation underpin some long COVID complaints, a modulator like vitamin D might nudge recovery in the right direction for certain people.
The trial team was upfront about limitations that affect how broadly these results can be applied. The study was run remotely and most participants started supplements several days after their positive test, not before or immediately at infection. Ideally, according to the investigators, supplementation would begin earlier in the course of exposure or right at diagnosis to test whether timing changes the effect. Those timing issues mean the observed signal for long COVID needs to be confirmed under different conditions and timing regimens.
Because the signal was modest and emerged mainly among adherent participants, larger and more targeted studies are required to sort signal from noise. The researchers note that different doses, longer treatment windows, or trials that enroll people before exposure might show a different pattern. Teams are already planning follow-up work that will look specifically at people already struggling with persistent post-COVID symptoms to see whether vitamin D can help as a treatment rather than a preventive nudge.
For now, the take-away is pragmatic: high-dose vitamin D taken for a short course after diagnosis did not change how sick people got in the acute phase, but it delivered a hint that lingering symptoms might be slightly less likely for those who followed the regimen closely. That hint is worth studying further, but it is not yet a green light for broad treatment recommendations or a substitute for established COVID care practices. Ongoing trials will be key to answering whether vitamin D can be a useful tool in the fight against long COVID.
